Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes

Abstract Objectives pDCs and γδ T cells emerge as potent immune players participating in the pathophysiology of cancers, yet still remaining enigmatic while harbouring a promising potential for clinical translations. Despite strategic and closed missions, crosstalk between pDCs and γδ T cells has no...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pauline Girard, Eleonora Sosa Cuevas, Benedicte Ponsard, Stephane Mouret, Hugo Gil, Edwige Col, Florence De Fraipont, Nathalie Sturm, Julie Charles, Olivier Manches, Laurence Chaperot, Caroline Aspord
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	BTN3A immune subversion melanoma pDCs γδ T cells Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/cd84e9bba19f4244a20d06c6ed117e9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd84e9bba19f4244a20d06c6ed117e9c
record_format	dspace
spelling	oai:doaj.org-article:cd84e9bba19f4244a20d06c6ed117e9c2021-11-25T13:32:30ZDysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes2050-006810.1002/cti2.1329https://doaj.org/article/cd84e9bba19f4244a20d06c6ed117e9c2021-01-01T00:00:00Zhttps://doi.org/10.1002/cti2.1329https://doaj.org/toc/2050-0068Abstract Objectives pDCs and γδ T cells emerge as potent immune players participating in the pathophysiology of cancers, yet still remaining enigmatic while harbouring a promising potential for clinical translations. Despite strategic and closed missions, crosstalk between pDCs and γδ T cells has not been deciphered yet in cancers, especially in melanoma where the long‐term control of the tumor still remains a challenge. Methods This prompted us to explore the interplay between pDCs and γδ T cells in the context of melanoma, investigating the reciprocal features of pDCs or γδ T cells, the underlying molecular mechanisms and its impact on clinical outcomes. Results TLRL‐activated pDCs from the blood and tumor infiltrate of melanoma patients displayed an impaired ability to activate, to modulate immune checkpoints and trigger the functionality of γδ T cells. Conversely, γδ T cells from the blood or tumor infiltrate of melanoma patients activated by PAg were defective in triggering pDCs’ activation and modulation of immune checkpoints, and failed to elicit the functionality of pDCs. Reversion of the dysfunctional cross‐talks could be achieved by specific cytokine administration and immune checkpoint targeting. Strikingly, we revealed an increased expression of BTN3A on circulating and tumor‐infiltrating pDCs and γδ T cells from melanoma patients, but stressed out the potential impairment of this molecule. Conclusion Our study uncovered that melanoma hijacked the bidirectional interplay between pDCs and γδ T cells to escape from immune control, and revealed BTN3A dysfunction. Such understanding will help harness and synergise the power of these potent immune cells to design new therapeutic approaches exploiting their antitumor potential while counteracting their skewing by tumors to improve patient outcomes.Pauline GirardEleonora Sosa CuevasBenedicte PonsardStephane MouretHugo GilEdwige ColFlorence De FraipontNathalie SturmJulie CharlesOlivier ManchesLaurence ChaperotCaroline AspordWileyarticleBTN3Aimmune subversionmelanomapDCsγδ T cellsImmunologic diseases. AllergyRC581-607ENClinical & Translational Immunology, Vol 10, Iss 11, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	BTN3A immune subversion melanoma pDCs γδ T cells Immunologic diseases. Allergy RC581-607
spellingShingle	BTN3A immune subversion melanoma pDCs γδ T cells Immunologic diseases. Allergy RC581-607 Pauline Girard Eleonora Sosa Cuevas Benedicte Ponsard Stephane Mouret Hugo Gil Edwige Col Florence De Fraipont Nathalie Sturm Julie Charles Olivier Manches Laurence Chaperot Caroline Aspord Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes
description	Abstract Objectives pDCs and γδ T cells emerge as potent immune players participating in the pathophysiology of cancers, yet still remaining enigmatic while harbouring a promising potential for clinical translations. Despite strategic and closed missions, crosstalk between pDCs and γδ T cells has not been deciphered yet in cancers, especially in melanoma where the long‐term control of the tumor still remains a challenge. Methods This prompted us to explore the interplay between pDCs and γδ T cells in the context of melanoma, investigating the reciprocal features of pDCs or γδ T cells, the underlying molecular mechanisms and its impact on clinical outcomes. Results TLRL‐activated pDCs from the blood and tumor infiltrate of melanoma patients displayed an impaired ability to activate, to modulate immune checkpoints and trigger the functionality of γδ T cells. Conversely, γδ T cells from the blood or tumor infiltrate of melanoma patients activated by PAg were defective in triggering pDCs’ activation and modulation of immune checkpoints, and failed to elicit the functionality of pDCs. Reversion of the dysfunctional cross‐talks could be achieved by specific cytokine administration and immune checkpoint targeting. Strikingly, we revealed an increased expression of BTN3A on circulating and tumor‐infiltrating pDCs and γδ T cells from melanoma patients, but stressed out the potential impairment of this molecule. Conclusion Our study uncovered that melanoma hijacked the bidirectional interplay between pDCs and γδ T cells to escape from immune control, and revealed BTN3A dysfunction. Such understanding will help harness and synergise the power of these potent immune cells to design new therapeutic approaches exploiting their antitumor potential while counteracting their skewing by tumors to improve patient outcomes.
format	article
author	Pauline Girard Eleonora Sosa Cuevas Benedicte Ponsard Stephane Mouret Hugo Gil Edwige Col Florence De Fraipont Nathalie Sturm Julie Charles Olivier Manches Laurence Chaperot Caroline Aspord
author_facet	Pauline Girard Eleonora Sosa Cuevas Benedicte Ponsard Stephane Mouret Hugo Gil Edwige Col Florence De Fraipont Nathalie Sturm Julie Charles Olivier Manches Laurence Chaperot Caroline Aspord
author_sort	Pauline Girard
title	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes
title_short	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes
title_full	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes
title_fullStr	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes
title_full_unstemmed	Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes
title_sort	dysfunctional btn3a together with deregulated immune checkpoints and type i/ii ifn dictate defective interplay between pdcs and γδ t cells in melanoma patients, which impacts clinical outcomes
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/cd84e9bba19f4244a20d06c6ed117e9c
work_keys_str_mv	AT paulinegirard dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT eleonorasosacuevas dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT benedicteponsard dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT stephanemouret dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT hugogil dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT edwigecol dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT florencedefraipont dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT nathaliesturm dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT juliecharles dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT oliviermanches dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT laurencechaperot dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes AT carolineaspord dysfunctionalbtn3atogetherwithderegulatedimmunecheckpointsandtypeiiiifndictatedefectiveinterplaybetweenpdcsandgdtcellsinmelanomapatientswhichimpactsclinicaloutcomes
_version_	1718413463474143232

Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes

Ejemplares similares